Clinical Study

Influence of Age, Past Smoking, and Disease Severity on TLR2, Neutrophilic Inflammation, and MMP-9 Levels in COPD

Table 1

Clinical characteristics for all participants. Data are median (q1, q3) unless indicated.

COPDOlder healthy controlYounger healthy control

692922
Age, years mean (SD)70.0 (7.3)65.9 (6.8)*32.3 (10.0)*†<0.001
Sex, (%) males34 (49)15 (52)6 (27)0.157
Smoker, never/ex17/5213/1620/2*†<0.001
Pack years34.8 (18.3, 56.3)18.5 (2.1, 41.9)2.9, 4.50.056
Years since ceased smoking (exsmokers), mean (SD)19.8 (13.5)24.4 (17.5)17.3 (9.5)0.515
Atopic, (%)36 (52)8 (28)12 (55)0.057
More than 2 chest infections
reported in last year, (%)
18 (29)0 (0)0 (0)*0.005
SF-36 physical 33.2 (27.1, 42.6)53.1 (50.1, 56.2)*54.8 (52.9, 57.8)*<0.001
SF-36 mental52.0 (38.1, 59.4)57.5 (55.5, 60.5)*55.6 (54.4, 57.0)*<0.001
Bronchodilator response %, 9.6 (4.1, 15.3)4.5 (2.4, 6.9)*4.2 (2.6, 5.9)*<0.001
Bronchodilator response, (%)11 (16)1 (3)1 (5)0.127
FEV1% predicted, mean (SD)52.1 (15.4)102.8 (16.4)*108.7 (12.3)*<0.001
FEV1/FVC%, mean (SD)52.2 (11.5)77.5 (4.1)*84.8 (5.7)*<0.001
KCO% predicted, mean (SD)53.6 (23.8)81.1 (10.8)*86.7 (9.9)*†<0.001

versus COPD; versus older healthy control.
SF-36: a short form health survey of 36 questions generic measure of quality of life.